Literature DB >> 2513765

Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration.

R S Baltimore1, C D Christie, G J Smith.   

Abstract

Despite studies of the pathologic and microbiologic aspects of the lung in cystic fibrosis (CF), there is a lack of information on the lung localization of bacterial pathogens. Bacteriologic data come from cultures of sputum or accessible lung effluent from bronchoscopy. Our objective was to localize Pseudomonas aeruginosa (PA) in situ in order to provide descriptive data on the relationship between the presence of PA and disease of the surrounding tissue. Using stored, uncut blocks of preserved lung, we deparaffinized, cut, mounted, and reacted them with high-titer rabbit sera made to a mucoid strain of PA. The tissues were then reacted with a second antibody, biotinylated goat antirabbit immunoglobulin, developed using a peroxidase technique and counterstained with hematoxylin. PA organisms stained with heavy brown deposits and this was species-specific. In five patients with CF chronically colonized with PA, the organisms could easily be localized in multiple sections. Microscopic study demonstrated that location was generally endobronchiolar and associated with bronchiolar obliterative changes, mainly in small (less than 1 mm) airways. Extraluminal PA organisms were rare even when there was chronic interstitial inflammation. This study demonstrated the presence of PA at the location where physiologic damage in CF is most severe--the small bronchioles--strengthening the association between PA and pulmonary deterioration in CF.

Entities:  

Mesh:

Year:  1989        PMID: 2513765     DOI: 10.1164/ajrccm/140.6.1650

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  82 in total

1.  The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils.

Authors:  Kazuhiro Tateda; Yoshikazu Ishii; Manabu Horikawa; Tetsuya Matsumoto; Shinichi Miyairi; Jean Claude Pechere; Theodore J Standiford; Masaji Ishiguro; Keizo Yamaguchi
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 2.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  Delayed wound healing in diabetic (db/db) mice with Pseudomonas aeruginosa biofilm challenge: a model for the study of chronic wounds.

Authors:  Ge Zhao; Phillip C Hochwalt; Marcia L Usui; Robert A Underwood; Pradeep K Singh; Garth A James; Philip S Stewart; Philip Fleckman; John E Olerud
Journal:  Wound Repair Regen       Date:  2010-08-19       Impact factor: 3.617

4.  A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms.

Authors:  Hirotoshi Matsui; Victoria E Wagner; David B Hill; Ute E Schwab; Troy D Rogers; Brian Button; Russell M Taylor; Richard Superfine; Michael Rubinstein; Barbara H Iglewski; Richard C Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus.

Authors:  Ute Schwab; Lubna H Abdullah; Olivia S Perlmutt; Daniel Albert; C William Davis; Roland R Arnold; James R Yankaskas; Peter Gilligan; Heiner Neubauer; Scott H Randell; Richard C Boucher
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

Authors:  John J LiPuma; Sivaprakash Rathinavelu; Bridget K Foster; Jordan C Keoleian; Paul E Makidon; Linda M Kalikin; James R Baker
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 8.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

9.  Cloning and phenotypic characterization of fleS and fleR, new response regulators of Pseudomonas aeruginosa which regulate motility and adhesion to mucin.

Authors:  B W Ritchings; E C Almira; S Lory; R Ramphal
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8.

Authors:  E DiMango; H J Zar; R Bryan; A Prince
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.